NCT03158805View on ClinicalTrials.gov

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

October 11, 2022

Study Completion Date

January 1, 2023

Conditions
Bipolar DisorderObesity
Interventions
DRUG

LIRAGLUTIDE

3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

OTHER

Placebo

Placebo injection

Trial Locations (1)

45040

Lindner Center of HOPE, Mason

All Listed Sponsors
lead

Lindner Center of HOPE

OTHER

NCT03158805 - Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) | Biotech Hunter | Biotech Hunter